Cagrilintide cannot fully compensate for chronically inadequate sleep
According to FDA prescribing information, approximately 20% of participants experience gastrointestinal side effects with either medication, while 60-75% of patients report at least one adverse event of any type
Members access not just dosing protocols and pharmacokinetic data, but comprehensive lifestyle integration guides, community support from people at every stage of their weight management journey, and evidence-based strategies for maintaining results after treatment concludes
On average, people taking GLP-1 Treatments, Semaglutide or Tirzepatide eat about 30% less food than they would otherwise
It is not independent medical advice, does not guarantee eligibility, prescriptions, pricing, availability, or results, and is not a substitute for speaking with a licensed healthcare professional